LEXINGTON, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release fourth quarter and full year 2025 financial results prior to the market open on Thursday, March 12, 2026. In conjunction with the release, the Company’s management team will host a webcast conference ca ...

Core Viewpoint - Rapid Micro Biosystems, Inc. is set to present at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its innovative automation solutions for healthcare product manufacturing and quality control [1][2]. Company Overview - Rapid Micro Biosystems is a life sciences technology company that provides automation solutions aimed at improving the manufacturing and release processes of healthcare products, including biologics, vaccines, cell and gene therapies, and sterile injectables [3]. - The company's flagship product, the Growth Direct system, modernizes microbial quality control (MQC) testing workflows, enhancing operational efficiency, accuracy, and compliance with data integrity regulations [3]. - The company is headquartered in Lexington, Massachusetts, with manufacturing facilities in Lowell, Massachusetts, and additional locations in Switzerland, Germany, and the Netherlands [3].

Core Insights - Rapid Micro Biosystems reported strong third quarter results with total revenue of $7.8 million, a 3% increase from $7.6 million in the same quarter of 2024 [3][8] - The company achieved record consumable revenue and a 32% increase in recurring revenue compared to the previous year, driven by strong service growth [2][8] - A significant multi-system order was received from a top global biopharma customer, marking the largest order in the company's history, which is expected to contribute to growth in 2026 and beyond [2][9][10] Financial Performance - Total revenue for Q3 2025 was $7.8 million, up 3% from $7.6 million in Q3 2024, with product revenue remaining flat at $5.2 million and service revenue increasing by 12% to $2.6 million [3][8] - Recurring revenue rose by 32% to $4.8 million compared to $3.7 million in Q3 2024, indicating strong demand for consumables and service contracts [3][8] - Gross margin improved to 9%, up from 8% in the previous year, reflecting better cost management [4][8] Cost Management - Total cost of revenue increased by 2% to $7.1 million in Q3 2025, while total operating expenses decreased by 5% to $12.1 million [4][5] - General and administrative expenses decreased by 1%, R&D expenses decreased by 2%, and sales and marketing expenses saw a significant drop of 14% compared to Q3 2024 [5] Net Loss and Cash Position - The net loss for Q3 2025 was $11.5 million, slightly higher than the $11.3 million loss in Q3 2024, with net loss per share remaining at $0.26 for both periods [6][8] - As of September 30, 2025, the company had approximately $42 million in cash, cash equivalents, short-term investments, and restricted cash [6][22] Future Outlook - The company raised its full-year 2025 total revenue guidance to at least $33 million, anticipating at least 27 Growth Direct system placements [10]

Core Insights - Rapid Micro Biosystems, Inc. is participating in the Stifel 2025 Healthcare Conference in New York, NY on November 11, 2025 [1][2] Company Overview - Rapid Micro Biosystems is a life sciences technology company that provides automation solutions for the efficient manufacturing and safe release of healthcare products, including biologics, vaccines, cell and gene therapies, and sterile injectables [3] - The company's flagship product, the Growth Direct system, modernizes microbial quality control testing workflows in pharmaceutical manufacturing, enhancing speed, accuracy, operational efficiency, and compliance with data integrity regulations [3] - The company is headquartered in Lexington, Massachusetts, with manufacturing in Lowell, Massachusetts, and additional locations in Switzerland, Germany, and the Netherlands [3]

Core Insights - Rapid Micro Biosystems, Inc. will release its third quarter 2025 financial results on November 7, 2025, before market opening [1] - The management team will host a webcast conference call at 8:30 a.m. ET on the same day, which will be accessible on the company's website [2] Company Overview - Rapid Micro Biosystems is a life sciences technology company that provides automation solutions for the efficient manufacturing and safe release of healthcare products, including biologics, vaccines, cell and gene therapies, and sterile injectables [3] - The company's flagship product, the Growth Direct system, modernizes microbial quality control testing workflows in pharmaceutical manufacturing, enhancing speed, accuracy, operational efficiency, and compliance with data integrity regulations [3] - The company is headquartered in Lexington, Massachusetts, with manufacturing in Lowell, Massachusetts, and additional locations in Switzerland, Germany, and the Netherlands [3]

Core Insights - Trinity Capital Inc. has committed $45 million in growth capital to Rapid Micro Biosystems, a company specializing in automation solutions for microbial quality control in healthcare product manufacturing [1][3][5] - Rapid Micro's Growth Direct platform enhances operational efficiency and data integrity, enabling faster and more accurate results in critical applications such as environmental monitoring and sterility testing [2][5] Company Overview - Trinity Capital Inc. is an alternative asset manager focused on private credit markets, having deployed over $4.7 billion across more than 420 investments since its inception in 2008 [4] - Rapid Micro Biosystems provides automation solutions that modernize manual microbial quality control testing workflows, significantly impacting biopharma manufacturing processes [5] Strategic Goals - The new capital from Trinity Capital will support Rapid Micro's global expansion of the Growth Direct platform and drive gross margin improvements through cost reductions and increased manufacturing efficiencies [3][4] - Rapid Micro aims to strengthen its financial position and focus on long-term revenue growth, margin expansion, and shareholder value enhancement [4]

Company Overview - Singular Genomics has raised approximately $450 million [10] - The company held $133 million in cash as of June 30, 2024 [10] - The company has approximately 195 employees [12] - The company has around 300 issued and pending patents [10, 12] Market Opportunity - The Next Generation Sequencing market is estimated at $7 billion in 2023, projected to reach $20 billion by 2030 [17] - The Spatial Sequencing market is estimated at $2 billion in 2023, projected to reach $11 billion by 2030, representing a 23% CAGR [19, 46] G4 Platform - The G4 platform offers flexibility with 1-4 flow cells and 16 lanes [28] - The G4 platform can achieve run times of 8-24 hours [28] - The G4 platform can produce up to 480 Gb output [28] G4X Platform - The G4X platform has a 40 cm² imaging area [77, 82] - The G4X platform offers high-throughput spatial sequencing with multiomic capabilities, including RNA, protein, and H&E [82]

Company Overview - Rapid Micro Biosystems, Inc. is an innovative life sciences technology company focused on providing automation solutions for the efficient manufacturing and safe release of healthcare products [3] - The company specializes in products such as biologics, vaccines, cell and gene therapies, and sterile injectables [3] - The flagship product, Growth Direct system, modernizes microbial quality control testing workflows in pharmaceutical manufacturing [3] Financial Results Announcement - The company will release its first quarter 2025 financial results on May 9, 2025, prior to market opening [1] - A webcast conference call will be hosted by the management team at 8:30 a.m. ET on the same day [2] - The live audio webcast will be available on the company's website and will be archived for replay [2] Operational Efficiency - The Growth Direct system automates quality control processes, leading to faster results, greater accuracy, and increased operational efficiency [3] - The system enhances compliance with data integrity regulations and supports quicker decision-making for healthcare product supply [3] - The company is headquartered in Lexington, Massachusetts, with manufacturing in Lowell, Massachusetts, and global locations in Switzerland, Germany, and the Netherlands [3]